A systems biology network model for genetic association studies of nicotine addiction and treatment

Pharmacogenetics and Genomics

Volumn 19, Issue 7, 2009, Pages 538-551

  Thomas, Paul D ^a   Mi, Huaiyu ^a   Swan, Gary E ^a   Lerman, Caryn ^d   Benowitz, Neal ^b   Tyndale, Rachel F ^e   Bergen, Andrew W ^a   Conti, David V ^c  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Disease risk; Genetic association; Nicotine dependence; Ontology; Smoking cessation treatment

Indexed keywords

NICOTINE;

ARTICLE; BEHAVIOR; BIOLOGY; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; KNOWLEDGE; MOLECULE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SMOKING CESSATION; STATISTICAL ANALYSIS; TOBACCO DEPENDENCE; BIOLOGICAL MODEL; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; REPRODUCIBILITY; SMOKING; SYSTEMS BIOLOGY;

DATABASES, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; MODELS, GENETIC; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SMOKING; SYSTEMS BIOLOGY; TOBACCO USE DISORDER;

EID: 67651232760     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832e2ced     Document Type: Article

References (79)

1. Williamson R. The molecular genetics of complex inherited diseases. Br J Cancer Suppl 1988; 9:14-16.
2. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449:851-861.
3. Viallefont V, Raftery AE, Richardson S. Variable selection and Bayesian model averaging in case-control studies. Stat Med 2001; 20:3215-3230.
4. Thomas DC, Witte JS, Greenland S. Dissecting effects of complex mixtures: who's afraid of informative priors? Epidemiology 2007; 18:186-190.
5. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81:328-345.
6. Bergen AW, Conti DV, Berg DVD, Lee W, Liu J, Li D et al. Dopamine genes and nicotine dependence in treatment seeking and community smokers. Neuropsychopharmacology 2009 (in press).
7. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008; 17:2834-2848.
8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
9. Pollock JD, Koustova E, Hoffman A, Shurtleff D, Volkow ND. Treatments for nicotine addiction should be a top priority. Lancet 2009; 24:24.
10. Swan GE, Hops H, Wilhelmsen KC, Lessov-Schlaggar CN, Cheng LS, Hudmon KS, et al. A genome-wide screen for nicotine dependence susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:354-360.
11. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 2007; 16:24-35.
12. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007; 16:36-49.
13. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008; 75:178-195.
14. Swan GE, Hudmon KS, Jack LM, Hemberger K, Carmelli D, Khroyan TV, et al. Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev 2003; 12:994-1005.
15. USDHHS, preventing tobacco use among young people: a report of the surgeon general. 1994, Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
16. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental monitoring moderates the importance of genetic and environmental influences on adolescent smoking. J Abnorm Psychol 2007; 116:213-218.
17. McCaffery JM, Papandonatos GD, Lyons MJ, Koenen KC, Tsuang MT, Niaura R. Educational attainment, smoking initiation and lifetime nicotine dependence among male Vietnam-era twins. Psychol Med 2007; 22:1-11.
18. Audrain-McGovern J, Rodriguez D, Wileyto EP, Schmitz KH, Shields PG. Effect of team sport participation on genetic predisposition to adolescent smoking progression. Arch Gen Psychiatry 2006; 63:433-441.
19. Coveney PV, Fowler PW. Modelling biological complexity: a physical scientist's perspective. J R Soc Interface 2005; 2:267-280.
20. Cortassa S, Aon MA, Rourke B, Jacques R, Tseng HJ, Marban E, Winslow RL. A computational model integrating electrophysiology, contraction, and mitochondrial bioenergetics in the ventricular myocyte. Biophys J 2006; 91:1564-1589.
21. Gennari JH, Neal ML, Carlson BE, Cook DL. Integration of multi-scale biosimulation models via light-weight semantics. Pac Symp Biocomput 2008; 13:414-425.
22. Kirschner DE, Chang ST, Riggs TW, Perry N, Linderman JJ. Toward a multiscale model of antigen presentation in immunity. Immunol Rev 2007; 216:93-118.
23. Gao Z, Barth AS, DiSilvestre D, Akar FG, Tian Y, Tanskanen A, et al. Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling. Physiol Genomics 2008; 35:222-230.
24. Rubin DL, Shah NH, Noy NF. Biomedical ontologies: a functional perspective. Brief Bioinform 2008; 9:75-90.
25. Simon J, Dos Santos M, Fielding J, Smith B. Formal ontology for natural language processing and the integration of biomedical databases. Int J Med Inform 2006; 75:224-231.
26. Rosse C, Mejino JL Jr. A reference ontology for biomedical informatics: the Foundational Model of Anatomy. J Biomed Inform 2003; 36:478-500.
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29.
28. Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007; 25:1251-1255.
29. Coulet A, Smail-Tabbone M, Napoli A, Devignes M. Suggested ontology for pharmacogenomics (SO-Pharm): modular construction and preliminary testing. Proc Workshop Knowl Syst Bioinform 2006; 648-657.
30. Noy NF, McGuinness D. Ontology development 101: a guide to creating your first ontology. Stanford Medical Informatics Technical Report SMI-2001-10880, 2001.
31. Diehl AD, Lee JA, Scheuermann RH, Blake JA. Ontology development for biological systems: immunology. Bioinformatics 2007; 23:913-915.
32. Noy NF, Crubezy M, Fergerson RW, Knublauch H, Tu SW, Vendetti J, Musen MA. Protege-2000: an open-source ontology-development and knowledge-acquisition environment. AMIA Annu Symp Proc 2003; 953:953.
33. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 2003; 19:524-531.
34. Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007; 35:D247-D252.
35. Piper ME, McCarthy DE, Baker TB. Assessing tobacco dependence: a guide to measure evaluation and selection. Nicotine Tob Res 2006; 8:339-351.
36. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006; 31:231-242.
37. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77:145-158.
38. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94:108-115.
39. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict 1991; 86:1119-1127.
40. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79:600-608.
41. Patterson F, Schnoll R, Wileyto E, Pinto A, Epstein L, Shields P, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 2:2.
42. Yokotani K, Okada S, Nakamura K. Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from the isolated rat adrenal gland. Eur J Pharmacol 2002; 446:83-87.
43. Tachikawa E, Mizuma K, Kudo K, Kashimoto T, Yamato S, Ohta S. Characterization of the functional subunit combination of nicotinic acetylcholine receptors in bovine adrenal chromaffin cells. Neurosci Lett 2001; 312:161-164.
44. Sala F, Nistri A, Criado M. Nicotinic acetylcholine receptors of adrenal chromaffin cells. Acta Physiol (Oxf) 2008; 192:203-212.
45. Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007; 74:1235-1246.
46. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007; 47:699-729.
47. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 2008; 13:368-373.
48. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE 2009; 4:e4653.
49. Ehringer MA, Clegg HV, Collins AC, Corley RP, Crowley T, Hewitt JK, et al. Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:596-604.
50. Hoft NR, Corley RP, McQueen MB, Schlaepfer IR, Huizinga D, Ehringer MA. Genetic association of the CHRNA6 and CHRNB3 genes with tobacco dependence in a nationally representative sample. Neuropsychopharmacology 2009; 34:698-706.
51. Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 2007; 64:1078-1086.
52. Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, Garcia V, et al. Ethnic-and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 2005; 14:1211-1219.
53. Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, Hopfer CJ, et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry 2008; 63:1039-1046.
54. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638-642.
55. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 2008; 4:e1000125.
56. Zeiger JS, Haberstick BC, Schlaepfer I, Collins AC, Corley RP, Crowley TJ, et al. The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Hum Mol Genet 2008; 17:724-734.
57. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18:14-20.
58. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 2008; 14:169-183.
59. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 2009; 20:1-17.
60. Smith B. Ontology. In: Floridi L, editor. Blackwell guide to the philosophy of computing and information. Oxford: Blackwell; 2003. pp. 155-166.
61. Rubin DL, Lewis SE, Mungall CJ, Misra S, Westerfield M, Ashburner M, et al. National Center for Biomedical Ontology: advancing biomedicine through structured organization of scientific knowledge. Omics 2006; 10:185-198.
62. Karp PD. Pathway databases: a case study in computational symbolic theories. Science 2001; 293:2040-2044.
63. Storey MA, Musen MA, Noy NF, Best C, Fergerson RW, Silva J. Jambalaya: an interactive environment for exploring ontologies. Int Conf Intell User Interfaces 2002; 1.
64. Day-Richter J, Harris MA, Haendel M, Lewis S. OBO-Edit-an ontology editor for biologists. Bioinformatics 2007; 23:2198-2200.
65. Kitano H, Funahashi A, Matsuoka Y, Oda K. Using process diagrams for the graphical representation of biological networks. Nat Biotechnol 2005; 23:961-966.
66. Splendiani A. RDFScape: semantic web meets systems biology. BMC Bioinformatics 2008; 9 (Suppl 4):S6.
67. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182.
68. Barrell D, Dimmer E, Huntley RP, Binns D, O0Donovan C, Apweiler R. The GOA database in 2009-an integrated gene ontology annotation resource. Nucleic Acids Res 2009; 37:D396-D403.
69. Hong EL, Balakrishnan R, Dong Q, Christie KR, Park J, Binkley G, et al. Gene ontology annotations at SGD: new data sources and annotation methods. Nucleic Acids Res 2008; 36:D577-D581.
70. Conti DV, Lewinger JP, Swan GE, Tyndale RF, Benowitz NL, Thomas PD. Using ontologies in hierarchical modeling of genes and exposures in biologic pathways, in NCI monograph 22: phenotypes, endophenotypes, and genetic studies of nicotine dependence. In: Swan GE, editor. 2009 (in press).
71. Kelley R, Ideker T. Systematic interpretation of genetic interactions using protein networks. Nat Biotechnol 2005; 23:561-566.
72. Kelley BP, Sharan R, Karp RM, Sittler T, Root DE, Stockwell BR, Ideker T. Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci U S A 2003; 100:11394-11399.
73. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10:37-48.
74. Pearl J. Causality: models, reasoning and inference. London: Cambridge University Press; 2000.
75. McCullagh P, Nelder JA. Generalized linear models. Boca Raton: Chapman; 1989.
76. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
77. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3:319-336.
78. Greenland S. Principles of multilevel modelling. Int J Epidemiol 2000; 29:158-167.
79. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306:640-643.